1. Scrip

Competition Piles Up: 100 Teneligliptin Brands Now In India

 
• By Anju Ghangurde

A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.

Marathon runners
A RECORD NUMBER OF TENELIGLIPTIN BRANDS ARE COMPETING ON THE INDIAN MARKET

Newcomer teneligliptin has set a record of sorts with an estimated 100 brands (including its combination with metformin) on the Indian market in just over two years since it was first introduced in June 2015.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia